146 related articles for article (PubMed ID: 9823973)
41. Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review.
Zehentmayr F; Grambozov B; Kaiser J; Fastner G; Sedlmayer F
Thorac Cancer; 2020 Jun; 11(6):1375-1385. PubMed ID: 32323484
[TBL] [Abstract][Full Text] [Related]
42. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
[TBL] [Abstract][Full Text] [Related]
43. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
Sause WT; Scott C; Taylor S; Johnson D; Livingston R; Komaki R; Emami B; Curran WJ; Byhardt RW; Turrisi AT
J Natl Cancer Inst; 1995 Feb; 87(3):198-205. PubMed ID: 7707407
[TBL] [Abstract][Full Text] [Related]
44. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
Thirion P; Holmberg O; Collins CD; O'Shea C; Moriarty M; Pomeroy M; O'Sullivan C; Buckney S; Armstrong J
Radiother Oncol; 2004 May; 71(2):163-6. PubMed ID: 15110449
[TBL] [Abstract][Full Text] [Related]
45. Programming of radiotherapy in the treatment of non-small-cell lung cancer--a way to advance care.
Saunders MI
Lancet Oncol; 2001 Jul; 2(7):401-8. PubMed ID: 11905734
[TBL] [Abstract][Full Text] [Related]
46. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results.
Graham MV; Pajak TE; Herskovic AM; Emami B; Perez CA
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):819-25. PubMed ID: 7860394
[TBL] [Abstract][Full Text] [Related]
47. Cancer Trials Ireland (ICORG) 06-34: A multi-centre clinical trial using three-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer.
McDermott RL; Armstrong JG; Thirion P; Dunne M; Finn M; Small C; Byrne M; O'Shea C; O'Sullivan L; Shannon A; Kelly E; Hacking DJ
Radiother Oncol; 2018 May; 127(2):253-258. PubMed ID: 29548561
[TBL] [Abstract][Full Text] [Related]
48. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
[TBL] [Abstract][Full Text] [Related]
49. Radiobiological prediction of normal tissue toxicities and tumour response in the radiotherapy of advanced non-small-cell lung cancer.
Singer JM; Price P; Dale RG
Br J Cancer; 1998 Dec; 78(12):1629-33. PubMed ID: 9862575
[TBL] [Abstract][Full Text] [Related]
50. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
[TBL] [Abstract][Full Text] [Related]
51. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
Pöttgen C; Eberhardt WE; Gauler T; Krbek T; Berkovic K; Jawad JA; Korfee S; Teschler H; Stamatis G; Stuschke M
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):809-15. PubMed ID: 19427744
[TBL] [Abstract][Full Text] [Related]
52. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study.
van Baardwijk A; Bosmans G; Boersma L; Wanders S; Dekker A; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1394-401. PubMed ID: 18258380
[TBL] [Abstract][Full Text] [Related]
53. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study.
Xu Y; Zheng X; Bai X; Li P; Ma H; Wang J; Hu X; Chen M
Oncotarget; 2017 Jul; 8(30):49084-49092. PubMed ID: 28467775
[TBL] [Abstract][Full Text] [Related]
54. Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer.
Kelsey CR; Das S; Gu L; Dunphy FR; Ready NE; Marks LB
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):997-1004. PubMed ID: 26581138
[TBL] [Abstract][Full Text] [Related]
55. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
Socinski MA; Morris DE; Halle JS; Moore DT; Hensing TA; Limentani SA; Fraser R; Tynan M; Mears A; Rivera MP; Detterbeck FC; Rosenman JG
J Clin Oncol; 2004 Nov; 22(21):4341-50. PubMed ID: 15514375
[TBL] [Abstract][Full Text] [Related]
56. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Marks LB; Garst J; Socinski MA; Sibley G; Blackstock AW; Herndon JE; Zhou S; Shafman T; Tisch A; Clough R; Yu X; Turrisi A; Anscher M; Crawford J; Rosenman J;
J Clin Oncol; 2004 Nov; 22(21):4329-40. PubMed ID: 15514374
[TBL] [Abstract][Full Text] [Related]
57. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
[TBL] [Abstract][Full Text] [Related]
58. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
[TBL] [Abstract][Full Text] [Related]
59. Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO)-Lung Working Group.
Parisi G; Mazzola R; Ciammella P; Timon G; Fozza A; Franceschini D; Navarria F; Bruni A; Perna M; Giaj-Levra N; Alongi F; Scotti V; Trovo M
Radiol Med; 2019 Feb; 124(2):136-144. PubMed ID: 30368721
[TBL] [Abstract][Full Text] [Related]
60. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Pajak TF
J Clin Oncol; 1990 Sep; 8(9):1543-55. PubMed ID: 2167952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
